Standout Papers

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-sma... 2015 2026 2018 2022 1.1k
  1. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (2016)
    Corey J. Langer, Shirish M. Gadgeel et al. The Lancet Oncology
  2. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (2016)
    Matthew D. Hellmann, Naiyer A. Rizvi et al. The Lancet Oncology
  3. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial (2015)
    Alice T. Shaw, Leena Gandhi et al. The Lancet Oncology
  4. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Scott Gettinger, Naiyer A. Rizvi et al. Journal of Clinical Oncology
  5. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology

Immediate Impact

8 by Nobel laureates 4 from Science/Nature 89 standout
Sub-graph 1 of 15

Citing Papers

Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
7 intermediate papers

Works of Hossein Borghaei being referenced

Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors
2017
Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.
2014
and 5 more

Author Peers

Author Last Decade Papers Cites
Hossein Borghaei 6996 4499 1315 1833 255 8.8k
Todd M. Bauer 5274 3986 2833 1386 257 8.2k
Leena Gandhi 5736 4042 2672 1786 143 8.5k
Thomas Bachelot 5672 2921 1815 1791 239 8.2k
Michael Smylie 7094 4305 2396 1587 92 8.9k
Jean‐Pierre Delord 5374 1977 2149 1651 257 8.1k
Scott Gettinger 9980 6665 2783 2654 255 12.8k
Mark M. Awad 7516 5631 2312 1285 268 10.4k
Justin F. Gainor 6392 6358 3223 1044 235 10.1k
Raanan Berger 4115 1893 2143 1612 158 7.1k
Yoon Kyung Jeon 4682 3401 2269 1653 272 8.9k

All Works

Loading papers...

Rankless by CCL
2026